

1 **Tryptophan and arginine metabolism is significantly altered at the time of admission in**
2 **hospital for severe COVID-19 patients: findings from longitudinal targeted metabolomics**
3 **analysis**

4 **Running title:** Metabolomic profiling in severe COVID-19 patients.

5 **Laura Anson^{*a} & Monta Ustinova^{*a}, Anna Terentjeva^b, Ingus Perkons^c, Liga Birzniece^a,**
6 **Vita Rovite^a, Baiba Rozentale^b, Ludmila Viksna^b, Oksana Kolesova^b, Kristaps Klavins^d,**
7 **Janis Klovins^{a#}.**

8 ^aLatvian Biomedical Research and Study Centre, Ratsupites iela 1, Riga, Latvia, LV-1067.

9 ^bRiga Stradins University, Dzirciema iela 16, Riga, Latvia, LV-1007.

10 ^cInstitute of Food Safety, Animal Health and Environment (BIOR), Lejupes iela 3, Riga, Latvia,
11 LV-1076.

12 ^dRiga Technical University, Kalku iela 1, Riga, Latvia, LV-1658.

13 ^{*}Laura Anson and Monta Ustinova share the co-first authorship.

14 LA contributed in the sample analysis, patient recruitment process and sample collection, data
15 analysis and interpretation, drafting the manuscript.

16 MU contributed in patient recruitment process and sample collection, data analysis and
17 interpretation, funding acquisition, drafting the manuscript.

18 #Corresponding author: Klovins@biomed.lu.lv

19 Word count for the abstract: 160

20 Word count for the main text: 1133

21

22

23 **Abstract**

24 The heterogeneity in severity and outcome of COVID-19 cases points out the urgent need
25 for early molecular characterization of patients followed by risk-stratified care. The main
26 objective of this study was to evaluate the fluctuations of serum metabolomic profiles of
27 COVID-19 patients with severe illness during the different disease stages in a longitudinal
28 manner. We demonstrate a distinct metabolomic signature in serum samples of 32 hospitalized
29 patients at the acute phase compared to the recovery period, suggesting the tryptophan
30 (tryptophan, kynurenine, and 3-hydroxy-DL-kynurenine) and arginine (citrulline and ornithine)
31 metabolism as contributing pathways in the immune response to SARS-CoV-2 with a potential
32 link to the clinical severity of the disease. In addition, we provide evidence for glutamine
33 metabolism in M2 macrophages as a complementary process and contribution of phenylalanine
34 and tyrosine in the molecular mechanisms underlying the severe course of the infection. In
35 conclusion, our results provide several functional metabolic markers for disease progression and
36 severe outcome with potential clinical application.

37 **Importance**

38 Although the host defense mechanisms against SARS-CoV-2 infection are still poorly
39 described, they are of central importance in shaping the course of the disease and the possible
40 outcome. Metabolomic profiling may complement the lacking knowledge of the molecular
41 mechanisms underlying clinical manifestations and pathogenesis of COVID-19. Moreover, early
42 identification of metabolomics-based biomarker signatures is proved to serve as an effective
43 approach for the prediction of disease outcome. Here we provide the list of metabolites
44 describing the severe, acute phase of the infection and bring the evidence of crucial metabolic

45 pathways linked to aggressive immune responses. Finally, we suggest metabolomic phenotyping
46 as a promising method for developing personalized care strategies in COVID-19 patients.

47 **Main text**

48 More than a year has passed since the World Health Organization (WHO) announced the
49 COVID-19 outbreak as a pandemic in March 2020, following the rapid spread of the SARS-
50 CoV-2 virus (1). The clinical course of COVID-19 is versatile, the infection of the SARS-CoV-2
51 virus not only varies in its severity from asymptomatic or mild and moderate respiratory disease
52 (80%) to clinically severe or critical life-threatening disease (20%) but also varies in a range of
53 organs the disease can affect (2, 3). Diverse clinical trajectories seem to be the result of the
54 immune response differences between individuals (4).

55 Multiple innate and adaptive immune system pathways that produce inflammatory
56 molecules against the virus and virus-infected human cells are triggered after the SARS-CoV-2
57 entry in the cell, with characteristic overexpression of proinflammatory cytokines (e.g. IL-6,
58 TNF α , IFN- γ) known as cytokine storm in the most severe cases (4–6). The host's immune
59 responses typically involve changes in metabolic processes at the cellular level, reflecting the
60 host-defense mediators and underlying mechanisms (7).

61 Detailed understanding of the molecular mechanisms behind COVID-19 pathogenesis and
62 inflammatory response is needed to predict and reduce individual risks, develop therapeutic
63 strategies, and reduce the overall ~2% mortality rate (mortality in hospitalized patients can be up
64 to 30%) (8, 9). The human blood sera metabolome (defined as small molecules <1500–2000 Da)
65 reflects the organism's metabolic state and is widely used to gain a deeper understanding of the
66 pathogenesis of diseases. Recent reports of metabolomics studies highlight the pivotal role of
67 cellular metabolites in programming immune response to SARS-CoV-2 infection (10–13).

68 Considering the extremely high heterogeneity of the COVID-19 disease and lack of promising
69 predictive biomarkers, we believe that implications of longitudinal metabolite profiling may be
70 beneficial in understanding the underlying mechanisms of the diverse course of the disease and
71 promote the early identification of people at increased risk of severe illness from COVID-19 and
72 related complications.

73 We performed quantitative targeted metabolome analysis with liquid chromatography-
74 mass spectrometry (LC-MS) in blood sera of 32 hospitalized COVID-19 patients at the acute
75 phase (time of admission at the hospital) and the recovery phase (40 ± 14.92 days) of the disease
76 (see Text S1 in the supplemental material for a detailed description of methods). Written
77 informed consent was obtained from every participant before their inclusion in the study, and the
78 study protocol was approved by the Central Medical Ethics Committee of Latvia (No. 01-
79 29.1.2/928).

80 As expected, the clinical blood tests revealed abnormal hematological parameters for the
81 majority of study participants at the time of hospitalization, with a high variation in platelet
82 ($202.94 \pm 65.26 \mu\text{L}$) levels and low lymphocyte measurements ($0.64 \pm 0.56 \mu\text{L}$), which coincides
83 with previously reported lymphopenia as the hallmark of severe COVID-19 cases. We also
84 observed a high variation of several markers (e.g. alanine aminotransferase, bilirubin, lactate C-
85 reactive protein) indicating renal and hepatic dysfunction, myocarditis, inflammation, and
86 coagulation, which confirms the systemic response to the infection in our study cohort(2, 14)
87 (see Table S1 in the supplemental material).

88 Out of 51 metabolites analyzed by LC-MS, 22 metabolites showed significantly altered
89 levels (paired t-test, $\text{FDR} < 0.05$) in the serum samples during the acute phase in comparison to
90 the recovery phase (Table 1), where concentrations for 16 compounds were significantly

91 elevated, whereas 8 metabolites were decreased. The hierarchical clustering and principal
92 component analysis of the obtained metabolomic profiles showed clear metabolomics-based
93 discrimination of samples collected in different phases of the disease (Figure1. A and B),
94 indicating an altered metabolic activity during infection. Pathway analysis revealed 13
95 significantly enriched pathways (FDR<0.05), including phenylalanine, tyrosine and tryptophan
96 biosynthesis, D-glutamine and D-glutamate metabolism and arginine biosynthesis (Figure1 C,
97 Table S3). Statistical analysis was done with Metaboanalyst version 5.0 (15).

98 We found L-glutamine (Figure 1D) as the most significantly changed amino acid between
99 the paired samples with reduced acute phase concentrations. It is known that glutamine
100 deprivation and decreased glutaminolysis inhibits M2 macrophage polarization, which may
101 partly explain the hyperinflammatory state in severe COVID-19 cases (16, 17). Moreover, the
102 beneficial effect of glutamine has been proposed in multiple studies, where adding enteral L-
103 glutamine to the regular nutrition shortened the duration of hospitalization and improved the
104 outcome in moderate to severe COVID-19 cases (18, 19).

105 Two other amino acids involved in arginine catabolism through the Urea cycle: citrulline
106 (Figure 1D) and ornithine (Table 1) were found to significantly change between the acute and
107 recovery phases. However, alterations in the levels of L-arginine itself were not detected. Low
108 blood plasma citrulline levels have already been reported in COVID-19 patients, whereas in
109 patients with severe sepsis, the decreased citrulline levels are associated with acute respiratory
110 distress syndrome (11, 13, 20). Since arginine can be metabolized to creatine and then to
111 creatinine, both varying highly in our study cohort according to regular blood tests performed
112 during hospitalization, arginine catabolism may be implicated in disturbed kidney function of
113 COVID-19 patients (21).

114 Three out of 22 metabolites showing significantly changed levels between acute infection
115 and recovery phase are involved in the tryptophan-kynurenine pathway: L-tryptophan,
116 kynurenine, and 3-hydroxy-DL-kynurenine (Figure 1D, Table 1). The reduction of tryptophan
117 levels and increase of kynurenine, 3-hydroxy-DL-kynurenine in the acute phase supports the
118 conclusions of previous reports and confirms this pathway's key role in severe COVID-19 cases
119 (10, 11). *In vitro* experiments have shown that tryptophan deprivation sensitizes T cells to
120 apoptosis, inhibits proliferation of T cells, and plays a role in CD8 T-cell suppression in cancer
121 (22, 23). Notably, the tryptophan-kynurenine pathway shows a modulatory effect on the
122 macrophage-mediated responses by targeting the synthesis of the metabolic coenzyme
123 NAD⁺(24, 25). According to Thomas *et al.* dysregulated tryptophan metabolism, an essential
124 regulator of inflammation and immunity may be a potential explanation for severity in older
125 COVID-19 patients (Thomas et al., 2020).

126 Finally, we observed a significant difference in L-phenylalanine (Figure 1D) and tyrosine
127 levels in our cohort between the analyzed disease phases, both already suggested as metabolic
128 hot spots of COVID-19 before (26). In sepsis and HIV-1 infection, the increased phenylalanine
129 sera concentrations are linked to immune activation and increased cardiovascular event risk (27–
130 29). Although the mechanisms behind this association are not well studied, it is in line with
131 microvascular endothelial damage and higher coagulation risk characteristic to both: coronary
132 heart disease and severe COVID-19 (29). Phenylalanine and tyrosine are catabolized to
133 dopamine and epinephrine, and the latter has been employed in cardiac arrest as a result of
134 cytokine storm, characteristic to severe COVID-19 patients(30).

135 In conclusion, our study shows that metabolomic profiling provides novel insights into the
136 pathogenesis of host-defense mechanisms and may be further applied for rapid biomarker

137 discovery in infectious disease. These discoveries could show novel therapeutic strategies as
138 indirect targets to fasten the recovery process after severe COVID-19. To the best of our
139 knowledge, this is the first longitudinal study covering metabolomic profiling of severe COVID-
140 19 patients.

141 **Data availability**

142 The raw data supporting the current study are available from the corresponding author on
143 request.

144 **Acknowledgments**

145 This study is funded by the Ministry of Education and Science, Republic of Latvia, project
146 "Establishment of COVID-19 related biobank and integrated platform for research data in
147 Latvia", project No. VPP-COVID-2020/1-0016.

148 We acknowledge The Boris and Inara Teterev Foundation for support to Riga Stradins
149 University in patient sample collection.

150 The authors acknowledge the Latvian Biomedical Research and Study Centre and the Genome
151 Database of the Latvian Population for providing the infrastructure, biological material, and data.

152 **Author contributions**

153 LA, KK, IP, LB performed the sample analysis; MU, VR, LA, BR, LV, OK were involved in
154 patient recruitment process and sample collection; AT ensured the clinical data acquisition; MU,
155 LA drafted the manuscript; JK provided critical revision of the manuscript; LA, KK, MU
156 performed the data analysis and interpretation; MU, JK collaborated in funding acquisition, JK

157 performed supervision and conceptualization of the study. All authors read and approved the
158 final manuscript.

159 **Declaration of Interests**

160 The authors declare no competing interests.

161 **References**

- 162 1. World Health Organization. 2020. Coronavirus disease 2019 (COVID-19) Situation
163 Report – 51.
- 164 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei
165 Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk
166 factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective
167 cohort study. *Lancet* 395:1054–1062.
- 168 3. Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons from the
169 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
170 72314 Cases from the Chinese Center for Disease Control and Prevention. *JAMA - J Am*
171 *Med Assoc* 323:1239–1242.
- 172 4. García LF. 2020. Immune Response , Inflammation , and the Clinical Spectrum of 11:4–8.
- 173 5. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian
174 DS. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-
175 19) in Wuhan, China. *Clin Infect Dis* 71:762–768.
- 176 6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. 2020. COVID-
177 19: consider cytokine storm syndromes and immunosuppression. *Lancet* 395:1033–1034.

- 178 7. Pearce EL, Pearce EJ. 2013. Metabolic Pathways in Immune Cell Activation and
179 Quiescence. *Immunity* 38:633–643.
- 180 8. Asch DA, Sheils NE, Islam N, Chen Y, Werner RM, Buresh J, Doshi JA. 2020. Variation
181 in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6
182 Months of the Pandemic *19104*:1–8.
- 183 9. Bellan M, Patti G, Hayden E, Azzolina D, Pirisi M, Acquaviva A, Aimaretti G, Valletti
184 PA, Angilletta R, Arioli R, Avanzi GC, Avino G, Balbo PE, Baldon G, Baorda F, Barbero
185 E, Baricich A, Barini M, Adesi FB, Battistini S, Beltrame M, Bertoli M, Bertolin S,
186 Bertolotti M, Betti M, Bobbio F, Boffano P, Boglione L, Borrè S, Bruccoli M, Calzaducca
187 E, Cammarata E, Cantaluppi V, Cantello R, Capponi A, Carriero A, Casciaro FG, Castello
188 LM, Ceruti F, Chichino G, Chirico E, Cisari C, Cittone MG, Colombo C, Comi C, Croce
189 E, Daffara T, Danna P, Corte F Della, Vecchi S De, Dianzani U, Benedetto D Di, Esposto
190 E, Faggiano F, Falaschi Z, Ferrante D, Ferrero A, Gagliardi I, Gaidano G, Galbiati A,
191 Gallo S, Garavelli PL, Gardino CA, Garzaro M, Gastaldello ML, Gavelli F, Gennari A,
192 Giacomini GM, Giacone I, Via VG, Giolitti F, Gironi LC, Gramaglia C, Grisafi L, Inserra
193 I, Invernizzi M, Krenqli M, Labella E, Landi IC, Landi R, Leone I, Lio V, Lorenzini L,
194 Marzari L, Marzullo P, Mennuni M, Montabone C. 2020. Fatality rate and predictors of
195 mortality in an Italian cohort of hospitalized COVID □ 19 patients. *Sci Rep* 1–10.
- 196 10. Blasco H, Bessy C, Plantier L, Lefevre A, Piver E, Bernard L, Marlet J, Stefic K, Benz-de
197 Bretagne I, Cannet P, Lumbu H, Morel T, Boulard P, Andres CR, Vourc’h P, Hérault O,
198 Guillon A, Emond P. 2020. The specific metabolome profiling of patients infected by
199 SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine
200 metabolism. *Sci Rep* 10:1–12.

- 201 11. Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, Hudson KE,
202 Zimring JC, Hansen KC, Hod EA, Spitalnik SL, D’Alessandro A. 2020. COVID-19
203 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and
204 renal status. *JCI Insight* 5.
- 205 12. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, Ge W, Liu
206 W, Liang S, Chen H, Zhang Y, Li J, Xu J, He Z, Chen B, Wang J, Yan H, Zheng Y, Wang
207 D, Zhu J, Kong Z, Kang Z, Liang X, Ding X, Ruan G, Xiang N, Cai X, Gao H, Li L, Li S,
208 Xiao Q, Lu T, Zhu YJ, Liu H, Chen H, Guo T. 2020. Proteomic and Metabolomic
209 Characterization of COVID-19 Patient Sera. *SSRN Electron J*
210 <https://doi.org/10.1101/2020.04.07.20054585>.
- 211 13. Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, Morillon A-C, Chin S-T,
212 Ryan M, Begum S, Bong SH, Coudert JD, Edgar D, Raby E, Pettersson S, Richards T,
213 Holmes E, Whiley L, Nicholson JK. 2021. Systemic Perturbations in Amine and
214 Kynurenine Metabolism Associated with Acute SARS-CoV-2 Infection and Inflammatory
215 Cytokine Responses. *J Proteome Res* <https://doi.org/10.1021/acs.jproteome.1c00052>.
- 216 14. Henry BM, Helena M, Oliveira S De, Benoit S. 2020. Hematologic , biochemical and
217 immune biomarker abnormalities associated with severe illness and mortality in
218 coronavirus disease 2019 (COVID-19): a meta-analysis 58:1021–1028.
- 219 15. Xia J, Wishart DS. 2011. Web-based inference of biological patterns, functions and
220 pathways from metabolomic data using MetaboAnalyst. *Nat Protoc* 6:743–760.
- 221 16. Liu P-S, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng W-C, Chou C-H,
222 Vavakova M, Muret C, Debackere K, Mazzone M, Huang H-D, Fendt S-M, Ivanisevic J,

- 223 Ho P-C. 2017. α -ketoglutarate orchestrates macrophage activation through metabolic and
224 epigenetic reprogramming. *Nat Immunol* 18:985–994.
- 225 17. Martinez FO, Combes TW, Orsenigo F, Gordon S. 2020. Monocyte activation in systemic
226 Covid-19 infection: Assay and rationale. *EBioMedicine* 59:102964.
- 227 18. Cengiz M, Uysal BB, Ikitimur H, Ozcan E, Aktepe E, Yavuzer H, Yavuzer S. 2020. Effect
228 of oral L -Glutamine supplementation on Covid-19 treatment 33:24–31.
- 229 19. Obayan AOE. 2021. Infectious Diseases and Epidemiology Overview of the Rationale for
230 L-Glutamine Treatment in Moderate-Severe COVID-19 Infection Proposed Flowchart of
231 In fl ammatory Response In COVID-19 Infec □ on 7:1–7.
- 232 20. Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW,
233 Wheeler AP, Bernard GR, Summar ML. 2013. Low plasma citrulline levels are associated
234 with acute respiratory distress syndrome in patients with severe sepsis 1–8.
- 235 21. Reyes AA, Karl IE, Klahr S. 1994. Role of arginine in health and in renal disease. *Am J*
236 *Physiol Physiol* 267:F331–F346.
- 237 22. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. 2002. Tryptophan
238 deprivation sensitizes activated T cells to apoptosis prior to cell division. *Immunology*
239 107:452–460.
- 240 23. Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K,
241 Borges VF, Slansky JE, Richer JK. 2019. A Role for Tryptophan-2,3-dioxygenase in CD8
242 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient
243 Plasma. *Mol Cancer Res* 17:131 LP – 139.

- 244 24. Minhas PS, Liu L, Moon PK, Joshi AU, Dove C, Mhatre S, Contrepois K, Wang Q, Lee
245 BA, Coronado M, Bernstein D, Snyder MP, Migaud M, Majeti R, Mochly-Rosen D,
246 Rabinowitz JD, Andreasson KI. 2019. Macrophage de novo NAD⁺ synthesis specifies
247 immune function in aging and inflammation. *Nat Immunol* 20:50–63.
- 248 25. Van Gool F, Gallí M, Gueydan C, Kruys V, Prevot P-P, Bedalov A, Mostoslavsky R, Alt
249 FW, De Smedt T, Leo O. 2009. Intracellular NAD levels regulate tumor necrosis factor
250 protein synthesis in a sirtuin-dependent manner. *Nat Med* 15:206–210.
- 251 26. Pang Z, Zhou G, Chong J, Xia J. 2021. Comprehensive meta-analysis of covid-19 global
252 metabolomics datasets. *Metabolites* 11:1–14.
- 253 27. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. 2010. Increased
254 blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective
255 antiretroviral therapy. *Brain Behav Immun* 24:403–408.
- 256 28. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. 2008. Serum
257 phenylalanine in patients post trauma and with sepsis correlate to neopterin
258 concentrations. *Amino Acids* 35:303–307.
- 259 29. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, Ghorbani
260 A, Artati A, Wang Q, Tiainen M, Kangas AJ, Kettunen J, Kaikkonen J, Mikkilä V, Jula A,
261 Kähönen M, Lehtimäki T, Lawlor DA, Gaunt TR, Hughes AD, Sattar N, Illig T, Adamski
262 J, Wang TJ, Perola M, Ripatti S, Vasan RS, Raitakari OT, Gerszten RE, Casas J-P,
263 Chaturvedi N, Ala-Korpela M, Salomaa V. 2015. Metabolite profiling and cardiovascular
264 event risk: a prospective study of 3 population-based cohorts. *Circulation* 2015/01/08.
265 131:774–785.

266 30. Luo P, Liu D, Li J. 2021. Epinephrine use in COVID-19: friend or foe? *Eur J Hosp Pharm*
267 28:e1 LP-e1.

268

269 **Figures**

270 **Figure 1. Targeted metabolomic analysis of longitudinal serum samples of hospitalized**
271 **COVID-19 patients.** (A) Heatmap and hierarchical clustering of top 22 significantly altered
272 metabolites. Each column represents one sample: (0, green) - samples collected in the acute
273 phase, (1, red) - samples collected during the recovery phase, each row conforms to a specific
274 metabolite expressed in normalized, log transformed concentration value. (B) Principal
275 component analysis showing clear discrimination of samples collected in the acute and recovery
276 phases of infection based on the obtained metabolite profiles. (C) Scatter plot representing the
277 most relevant metabolic pathways from KEGG library arranged by adjusted p-values (obtained
278 by Global Test pathway enrichment analysis) on Y-axis, and pathway impact values (from
279 pathway topology analysis) on X-axis. The node color is based on its p-value and the node radius
280 is determined based on their pathway impact values. (D) Boxplots showing the normalized levels
281 of the most functionally relevant metabolites during the acute phase (0) and the recovery phase
282 (1) of the infection, described as the minimum value, the first quartile, the median, the third
283 quartile, and the maximum value with the black dots representing each sample.

284

285

286

287

288

289 **Tables**

290 Table 1. Serum metabolites showing significantly altered levels comparing measures obtained
291 during the acute phase and recovery phase of the disease.

Compound	Fold change	False discovery rate
L-Glutamine	0.72	5.71E-08
Citrulline	0.48	9.16E-08
3-Hydroxy-DL-Kynurenine	10.51	6.79E-07
L-Phenylalanine	1.33	6.79E-07
L-Methionine	1.47	1.62E-06
Isovalerylcarnitine	2.01	1.78E-06
4-Hydroxyproline	0.42	1.99E-06
Kynurenine	1.71	2.67E-06
L-Asparagine	1.51	3.88E-05
L-Glutamic acid	1.65	4.61E-05
L-Valine	1.26	7.73E-05
Carnitine	1.25	8.90E-05
L-Tryptophan	0.83	2.87E-04
L-Tyrosine	1.14	2.87E-04
L-Threonine	1.45	2.15E-03
L-Proline	0.86	3.23E-03
Taurine	1.36	6.01E-03

Ornithine	1.37	9.45E-03
L-Lysine	1.08	1.15E-02
L-Isoleucine	1.21	1.25E-02
L-Acetylcarnitine	1.21	2.34E-02
L-Octanoylcarnitine	0.75	3.85E-02

292

293 **Appendixes**

294 Text S1. Detailed Methods Description.

295 Table S1. Characteristics of the study participants.

296 Table S2. Data matrix with quantified metabolite concentrations for targeted compounds,
297 determined by ultra-performance liquid chromatography-mass spectrometry.

298 Table S3. Significant pathways based on enrichment procedures.

